Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CNTG logo CNTG
Upturn stock ratingUpturn stock rating
CNTG logo

Centogene B V (CNTG)

Upturn stock ratingUpturn stock rating
$0.14
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CNTG (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $1.52

1 Year Target Price $1.52

Analysts Price Target For last 52 week
$1.52Target price
Low$0.04
Current$0.14
high$0.55

Analysis of Past Performance

Type Stock
Historic Profit -65.69%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.43M USD
Price to earnings Ratio -
1Y Target Price 1.52
Price to earnings Ratio -
1Y Target Price 1.52
Volume (30-day avg) 1
Beta -0.67
52 Weeks Range 0.04 - 0.55
Updated Date 06/29/2025
52 Weeks Range 0.04 - 0.55
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.39

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -73.21%
Operating Margin (TTM) -63.29%

Management Effectiveness

Return on Assets (TTM) -26.76%
Return on Equity (TTM) -1375.33%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 70012544
Price to Sales(TTM) 0.08
Enterprise Value 70012544
Price to Sales(TTM) 0.08
Enterprise Value to Revenue 1.37
Enterprise Value to EBITDA -1.58
Shares Outstanding 29000100
Shares Floating 11780726
Shares Outstanding 29000100
Shares Floating 11780726
Percent Insiders 4.57
Percent Institutions 66.89

Analyst Ratings

Rating 1
Target Price 1.52
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Centogene B V

stock logo

Company Overview

overview logo History and Background

Centogene B.V. was founded in 2006 and is based in Rostock, Germany. It started as a spin-off from the University of Rostock. The company focuses on rare disease diagnostics and has expanded to offer broader genetic testing services over time, becoming a global leader in the field.

business area logo Core Business Areas

  • Diagnostics: Genetic testing services for rare diseases, including sequencing and interpretation of genetic data.
  • Pharmaceutical Solutions: Partnerships with pharmaceutical companies to support drug development, including patient identification and biomarker discovery.
  • Data Services: Utilizing a proprietary biodata platform to provide insights into rare diseases and genetic variants.

leadership logo Leadership and Structure

The leadership team includes experienced executives in diagnostics and biotechnology. The organizational structure involves various departments, including diagnostics, R&D, and commercial operations. Andria Lisa Williams serves as the CEO and Mahesh Chhatre as the CFO.

Top Products and Market Share

overview logo Key Offerings

  • Whole Exome Sequencing (WES): Comprehensive genetic testing to identify mutations across the exome. Centogene doesn't specifically publish market share, but they are considered a key player in rare disease diagnostics. Competitors include Invitae (NVTA), and Quest Diagnostics (DGX).
  • Whole Genome Sequencing (WGS): Complete sequencing of an individual's genome, providing the most comprehensive genetic information. Competitors include Illumina (ILMN) and Exact Sciences (EXAS).
  • Biomarker Discovery: Partnering with pharmaceutical companies to identify and validate biomarkers for drug development. Competitors include LabCorp (LH) and Charles River Laboratories (CRL).

Market Dynamics

industry overview logo Industry Overview

The genetic testing market is experiencing rapid growth due to advancements in sequencing technologies and increasing awareness of genetic diseases. The rare disease segment is particularly attractive, driven by unmet medical needs and Orphan Drug regulations.

Positioning

Centogene is positioned as a leading specialist in rare disease diagnostics. Its competitive advantages include its extensive biodata platform and its partnerships with pharmaceutical companies.

Total Addressable Market (TAM)

The global genetic testing market is estimated to reach hundreds of billions of dollars. Centogene is positioned within the rare disease diagnostics subset of this TAM, which is expected to grow substantially.

Upturn SWOT Analysis

Strengths

  • Proprietary biodata platform
  • Expertise in rare disease diagnostics
  • Established partnerships with pharmaceutical companies
  • Global presence

Weaknesses

  • Reliance on specific markets
  • Historically, profitability has been difficult to achieve
  • Intense competition in the genetic testing market
  • Regulatory hurdles

Opportunities

  • Expanding into new geographic markets
  • Developing new diagnostic tests
  • Increasing partnerships with pharmaceutical companies
  • Leveraging AI for data analysis

Threats

  • Increased competition from larger genetic testing companies
  • Changes in regulatory landscape
  • Reimbursement pressures from healthcare payers
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • NVTA
  • DGX
  • ILMN
  • EXAS
  • LH
  • CRL

Competitive Landscape

Centogene had a focused approach in rare diseases diagnostics. However, competitors have significantly larger resources and broader market coverage.

Growth Trajectory and Initiatives

Historical Growth: Historically, growth was primarily driven by increased demand for genetic testing and expansion into new markets.

Future Projections: Future projections are unavailable following delisting. Prior projections anticipated growth based on increased adoption of genomic medicine.

Recent Initiatives: Recent initiatives included partnerships with pharmaceutical companies for drug development and investments in its biodata platform.

Summary

Centogene focused on rare disease diagnostics, leveraging its biodata platform and partnerships. However, it faced challenges in achieving profitability and was ultimately delisted. The company needs to improve financial stability and address competitive pressures. The company had a competitive advantage on data but needs to ensure it stays ahead of competitors. Investors should be wary about the company's future due to delisting and past financial struggles.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (prior to delisting)
  • Market research reports
  • Analyst reports

Disclaimers:

Financial data may be outdated due to delisting. Market share figures are estimates.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Centogene B V

Exchange NASDAQ
Headquaters -
IPO Launch date 2019-11-07
CEO & Member of Management Board Ms. Kim Stratton
Sector Healthcare
Industry Diagnostics & Research
Full time employees 384
Full time employees 384

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.